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ABSTRACT 
BACKGROUND AND OBJECTIVE: Studies have shown that the increase in urotensin – II is associated with diabetes 
disorders. Considering that using herbal medicines for the treatment of diseases leads to fewer complications compared 
to most chemical drugs, the present study was conducted to investigate the effect of silymarin on glucose, and insulin 
levels and the expression of urotensin – II (U–II) and urotensin – II receptor (U–II R) genes in the liver tissue of type 2 
diabetic male rats. 
METHODS: In this experimental study, 36 male albino Wistar rats were randomly divided into 6 groups (n=6): 1. 
Control group; 2 and 3. Control groups treated with 60 and 120 mg / kg / day silymarin; 4. Type 2 diabetic group which 
received an intraperitoneal (i.p.) injection of 60 mg / kg streptozotocin and 120 mg / kg nicotinamide; 5 and 6. Diabetic 
rats treated with 60 and 120 mg/kg/day silymarin. After 60 days of treatment, serum and liver tissue samples were 
collected. Glucose, insulin, HOMA-IR index and liver enzymes were evaluated by spectrophotometry and ELISA 
methods, while gene expression in liver tissue was analyzed by Real-time PCR method. 
FINDINGS: Insulin levels increased significantly in diabetic groups treated with silymarin (60 and 120 mg/kg) (9.6±1.11 
and 9.8±0.96, respectively) in comparison with the diabetic control group (7.10±1.06) (p<0.05). Moreover, glucose level, 
HOMA-IR, liver enzymes, U–II and U – II R expression in diabetic group treated with silymarin significantly decreased 
compared to diabetic control group (p<0.05).    
CONCLUSION: The results of this study showed that administration of silymarin improves liver function in diabetic 
rats. 
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Introduction 
Diabetes mellitus is one of the most important 
metabolic disorders. This disease occurs due to various 
causes such as reduced insulin secretion or resistance to 
the function of this hormone (1). In 2017, the global 
prevalence of diabetes was 382 million people, which is 
predicted to reach 592 million people by 2035. Its 
prevalence is increasing dramatically, especially in 
developing countries like Iran (2). Diabetes is 
considered as one of the major causes of the incidence 
of hepatic disorders (3).  
Urotensin – II gene (U – II) with 11 amino acids has 
been identified as the strongest factor in vascular 
contraction in mammals. In humans, the U – II mRNA 
has been discovered in the heart, liver, kidneys, adrenal 
glands, placenta, spleen, and thymus glands tissues (4). 
The U-II molecule performs its actions through its 
receptor, which is G protein-coupled receptor. The U-II 
and U-II R systems are effective in insulin resistance, 
impaired glucose tolerance, impaired glucose transport 
to muscles via GLUT4, impaired pancreatic beta-cell 
function, and induction of type 2 diabetes (5). 
Therefore, U – II and U – II R systems are potential 
therapeutic goals in the treatment of diabetes-related 
disorders.  
Silymarin is the most important active ingredient in 
milk thistle (Silybum marianum), which consists of a 
group of chemicals called Flavonolignans (6,7). For 
centuries, the seeds of this plant have been used as a 
very useful drug for the treatment of liver disease, and 
they have been commercially manufactured and used 
since 1970 (3).  
Considering the importance of U – II and U – II R, 
and the fact that they have recently been considered as 
a new therapeutic goal in metabolic diseases, finding 
compounds, particularly with herbal origin, that 
decrease the expression of this genes is very important 
for diabete treatment. Therefore, the present study was 
conducted to investigate the effect of silymarin on 
glucose, insulin, HOMA-IR, liver enzymes and 
expression of U – II and U – II R genes in liver tissue of 
type 2 diabetic male rats.     
  
 
Methods 
This experimental study was carried out on 36 male 
Wistar rats (220±10 g). Animals were kept in animal 
house condition with free access to water and food and 
12/12h light-dark cycle. Then, the animals were 
randomly divided into 6 groups (n=6): control group 
with normal nutrition, control groups treated with 60  
 
mg/kg and 120 mg/kg silymarin respectively, type 2 
diabetic group, and type 2 diabetic groups treated with 
60 mg/kg and 120 mg/kg silymarin respectively for 60 
days. To induce of type 2 diabetes, Fifteen minutes after 
injection of 60 mg/kg streptozotocin, nicotinamide 120 
mg/kg was injected intraperitoneally to the rats. To 
confirm diabetes, after seven days blood glucose were 
measured by glucometer. Rats with a fasting blood 
glucose above 150 were included in the study. Then, 
treatment started with silymarin (Livergol tablet as 
suspension in normal saline and once a day for 60 days 
by oral gavage) (8). All procedures on the animals were 
based on the Ethical Guidelines for the Use of Animals 
in Research and approval at the Ethics Committee of 
Hamadan University of Medical Sciences 
(IR.UMSHA.REC.1395.205).  
At the end of the study, the rats were anesthetized 
with ketamine (50 mg/kg) after overnight fast and serum 
samples were collected and kept for measuring liver 
enzymes and insulin. The liver tissue was kept at a 
temperature of -80 °C until performing gene expression.  
Measurement of fasting blood glucose, insulin and 
HOMA-IR levels: The fasting blood glucose levels 
were measured by ACCU-CHEK Aviva Blood Glucose 
Meter (Germany) after collecting blood from tail vein. 
Insulin was measured using ELISA Kit (Mercodia, 
Sweden). The Insulin resistance index (HOMA-IR) was 
evaluated using the following formula (4): 
 
HOMA-IR=Fasting insulin (μU/ml)×Fasting glucose 
(mg/dl)/405 
 
Measurement of Liver Enzymes: Serum levels of 
Alanine Aminotransferase (ALT), Aspartate 
Aminotransferase (AST), and Alkaline 
Aminotransferase (ALP) were measured through 
colorimetric by spectrophotometer in fasting condition.  
Evaluation of U – II and U – II R genes: To 
investigate the expression of U – II and U – II R genes, 
RNA extraction was performed by RNX-Plus solution 
(Sinaclon, Iran). The quality and quantity of the 
extracted RNA were determined by electrophoresis and 
NanoDrop (Fig 1). Then, cDNA synthesis was 
performed by Takara Kit. Then, 1 μg of synthesized 
cDNA entered the Real Time PCR reaction, which was 
carried out using SYBR Green Kit (Takara Co.). The 
primers required for the reaction were designed by 
Primer 3 software (Table 1). β-Actin was used as the 
housekeeping gene. Finally, the results were analyzed 
by 2-ΔΔCt method (9).  
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Statistical analysis: All parameters were determined as the 
mean and standard deviation value and were analyzed with 
SPSS-16 (Chicago, IL). One-way ANOVA followed by the 
Tukey’s post hoc test was used to analyze the normal value 
that was evaluated by Kolmogorov–Smirnov test. P<0.05 was 
considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Agarose 1% gel electrophoresis of U–II, U–II R, β-Actin genes and Ladder 100bp. 
 
Table 1. The specifications of used primers 
 
Gene name  Primer sequence (5'->3') 
Primer length 
(bp) 
Product length 
(bp) 
Urotensin II 
Forward 5′GTCGTCATGGACAGGGTG3′ 18 
74 
Reverse 5′GAGGGTTTATTTCTCATAGTGG3′ 22 
Urotensin II 
receptor 
Forward 5′GCACGCCAGCATCTTCAC3′ 18 
101 
Reverse 5′TGGTCCCAAAGAGCAACG3′ 18 
β-Actin 
Forward 5′CCCGCGAGTACAACCTTCT 3′ 19 
72 
Reverse 5′CGTCATCCATGGCGAACT 3′ 18 
 
Results 
The STZ/NIC injection increased blood glucose in 
the diabetic group (299.3±27.0) compared to the healthy 
control group (83.3±10.9) (p<0.01). In diabetic groups 
treated with 60 and 120 mg/kg silymarin (202.6±45.1 
and 182.5±35.8), blood glucose levels showed a 
significant decrease compared to the diabetic group 
(p<0.01).  
Moreover, the induction of diabetes reduced serum 
insulin levels in the diabetic group (7.10±1.06) 
compared to the control group (11.46±0.47) (p<0.01) 
(Table 2). In diabetic groups treated with doses of 60 
and 120 mg/kg silymarin (9.6±1.11 and 9.80±0.96), 
there was a significant increase in insulin levels 
compared to diabetic group (p<0.01). Furthermore, 
induction of diabetes increased the HOMA-IR levels in 
the diabetic group (5.79±0.90) compared to the control 
group (2.35±0.27) (p<0.01). The diabetic groups treated 
with 60 and 120 mg/kg silymarin (4.71±0.64 and 
4.35±0.56) showed a significant decrease in HOMA-IR 
levels compared to diabetic group (p<0.05). The activity  
 
of ALT (160.66±7.11), AST (239.16±14.17), and ALP 
(730.16±41.88) in the diabetic group increased 
significantly compared to the healthy control group 
(53.00±6.10, 108.33±6.59, and 250.50±19.59, 
respectively) (p<0.01) (Table 2). In the diabetic group 
treated with doses of 60 mg/kg (73.50±2.07, 
152.00±6.71, and 396.50±34.56) and 120 mg/kg 
(70.50±3.04, 140.50±10.44, and 431.83±24.92), 
significant decrease was observed in the activity of 
ALT, AST and ALP enzymes compared to the diabetic 
group (p<0.01). The expression of U–II and U–II R 
genes in the diabetic group (10.02±2.47 and 3.80±0.85) 
increased significantly compared to the control group 
(1±0.00 and 1±0.00) (p<0.01). Treatment with 
silymarin significantly reduced the expression of U – II 
(3.01±0.37 at the dose of 60 mg/kg, and 2.40±0.53 at 
the dose of 120 mg/kg) and U – II R (2.09±0.83 at the 
dose of 60 mg/kg, and 1.71±0.47 at the dose of 120 
mg/kg) genes compared with the diabetic group 
(p<0.01) (Fig 2).  
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Figure 2. The expression of (A) U–II and (B) U–II R genes in the liver tissue of the study groups (n=6) after 60 
days of treatment with silymarin (60 and 120 mg/kg). Data are shown as mean±SD. C: control group, S: Silymarin, 
D: Diabetic. Non-similar letters indicate significant difference. P<0.05 was considered significant 
 
Table 2. The level of glucose, insulin, insulin resistance index and liver enzymes in the study groups (n=6) after 
60 days of treatment with silymarin (60 and 120 mg/kg) 
Alanine 
Transaminase 
(U/L) 
Aspartate 
transaminase 
(U/L) 
Alkaline 
phosphatase 
(U/L) 
Insulin 
resistance index 
(HOMA-IR) 
Insulin 
(µU/ml) 
Fasting 
glucose 
(mg/dl) 
Variables 
Groups 
53.00±6.10 a 108.33±6.59 a 250.50±19.59 a 2.35±0.27 a 11.46±0.47a 83.3±10.9 a Control 
47.16±5.26 a 119.16 ±11.16a 267.16±20.74 a 2.24±0.26 a 11.96±0.67a 76.5±12.2 a 
Control + Silymarin 
60 mg/kg 
55.00±5.51 a 115.66±9.79 a 270.33±21.44 a 2.28±0.41 a 11.65±1.64a 79.5±13.8 a 
Control+Silymarin 
120 mg/kg 
160.66±7.11 b 239.16 ±14.17b 730.16 ±41.88b 5.79±0.90 b 7.10±1.06 b 229.3±27 b Diabetic 
73.50±2.07 a 152.00±6.71 c 396.50±34.56 c 4.71±0.64 c 9.60±1.11 c 202.6±45.1c 
Diabetic+Silymarin 
60 mg/kg 
70.50±3.04 a 140.50 ±10.44c 431.83±24.92 c 4.35±0.56 c 9.80±0.96 c 182.5±35.8c 
Diabetic+Silymarin 
120 mg/kg 
Data are shown as mean±SD. Non-similar letters indicate significant difference. P<0.05 was considered significant 
 
Discussion 
In this study, induction of type 2 diabetes in rats 
reduced insulin, increased glucose, HOMA-IR and the 
expression of U–II and U–II R genes compared to 
healthy control group. Moreover, treatment of diabetic 
animals with silymarin improved this parameters 
compared to control diabetic rats. Research has shown 
that in diabetes, the transport of glucose to the muscles 
is decreased, resulting in increased blood glucose levels 
(10). STZ is also introduced into a pancreatic beta cell 
via a glucose transporter (GLUT2) and causes DNA 
alkylation and this process induces poly ADP-
ribosylation. The poly ADP-ribosylation process 
reduces the levels of ATP and NAD in the cell. The 
exacerbation of ATP dephosphorylation, after the effect  
 
of STZ, creates a substrate for the xanthine oxidase 
enzyme, which leads to the formation of superoxide 
radicals and DNA damage, which causes the necrosis of 
the pancreatic beta cells, and this decreases serum 
insulin levels and increases serum glucose levels (11). 
In diabetic groups treated with 60 mg/kg and 120 mg/kg 
silymarin, blood glucose, insulin level and HOMA-IR 
improved compared with the diabetic group. In a study 
by Soto et al., it was reported that silymarin improves 
pancreatic beta cells by increasing the expression of 
pancreatic duodenal homeobox (Pdx1), increases 
insulin production, and thus decreases blood glucose 
(12). Hyperglycemia and dyslipidemia, which are the 
main characteristics of type 2 diabetes, impair the 
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function of pancreatic beta cells by decreasing the 
expression of Pdx1. Pdx1 also increases the expression 
of insulin, and proliferation and survival of pancreatic 
beta cells (13, 14).  
Furthermore, Pferschy-Wenzig et al., reported that 
the active ingredient of Isosilybin A in silymarin has 
PPAR-γ agonist properties. The PPAR-γ molecule is a 
target for thiazolidinedione’s, such as pioglitazone; 
these drugs increase the sensitivity of insulin to decrease 
blood glucose levels in type 2 diabetic patients (15). 
Similarly, in the studies of Alabdan, Tuorkey and Feng, 
treatment of diabetic rats with silymarin has been shown 
to improve blood glucose, protect the pancreatic beta 
cells, increase insulin secretion and improve HOMA-IR 
(16–18).  
It has been claimed that flavonoids in the silymarin 
extract, such as silybin and sylidianin may decrease 
insulin resistance and improve glucose metabolism in 
diabetic patients (19). In type 2 diabete mellitus, insulin 
resistance, dyslipidemia and increased blood glucose 
may damage different tissues, including the liver tissue 
(20). Increase in the activity of AST, ALT, and ALP 
enzymes is an appropriate marker to measure liver cell 
damage (21).  
In the early stages of liver damage, cytoplasmic 
enzymes leak into the blood stream due to increased 
penetrability of the hepatocyte membrane (22). 
Moreover, increased catabolism of proteins along with 
gluconeogenesis and the formation of urea that is 
observed in diabetes is likely to be responsible for 
increasing these transaminases in the blood (23). On the 
other hand, since insulin suppresses the gluconeogenic 
enzyme genes, and ALT is also a gluconeogenic 
enzyme, ALT production increases in the diabetes (24). 
In the present study, the results indicated an increase in 
liver aminotransferase enzyme in the diabetic group 
compared to healthy controls. It was also shown that 
treatment with silymarin significantly decreased liver 
damage markers in serum. Silymarin is a common 
treatment for hepatic diseases. Over 33% of people with 
chronic hepatitis C virus infection and cirrhosis have 
been reported to use silymarin for treatment (25, 26). 
Silymarin is prescribed in traditional medicine to 
improve liver disorders due to its antioxidant properties, 
increasing cellular glutathione and cell membrane 
stability, and it decreases liver damage markers through 
this mechanism (27).  
The result of the present study showed a treatment 
with silymarin significantly reduced the expression of U 
– II and U – II R genes in the liver tissue of treated 
diabetic groups compared to control diabetic group. 
Consistent with the results of the present study, the 
study of Rahimi et al., showed the effect of silymarin on 
reducing the expression of U – II and U – II R genes in 
the heart tissue of diabetic rats (4). In addition, total 
flavones of Rhododendron simsii Planch flower (TFR) 
was used in rats in the study of Cheng et al. This plant 
contains flavonoids that have antioxidant, anti-
inflammatory and anti-fibrosis properties. This study 
showed that TFR protected the heart of rats against heart 
attack by reducing the expression of U – II and U – II R 
genes (28). The results of the present study showed that 
silymarin has potential hypoglycemic properties, 
increases insulin levels and sensitivity. Silymarin 
reduced the expression of U – II and U – II R genes in 
the liver tissue of type 2 diabetic rats, which may as well 
reduce insulin resistance.  
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